pfizer glp 1 Readout Newsletter: Abeona, Pfizer, Regeneron, AstraZeneca Pfizer, Novo Nordisk bidding war
Description
Brito, J
The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies
and licensed to Kailera Therapeutics for regions outside of Greater China
doi: 10.1097/GOX.0000000000005427 110 DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellL
LLY: Writing review & editing, Writing original draft
